Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 20fludarabine phosphate 19Peripheral Blood Stem Cell Transplantation 18Whole-Body Irradiation 15Cyclosporine 12Mycophenolic Acid 11Etoposide 9Busulfan 9Prednisone 8Vincristine 7Tacrolimus 7Filgrastim 7Carboplatin 7Bortezomib 7Antilymphocyte Serum 7Methotrexate 6Everolimus 6Doxorubicin 6Vorinostat 5Rituximab 5Gemcitabine 5Therapeutics 4Radiotherapy 4Panobinostat 4Paclitaxel 4Melphalan 4Lenalidomide 4Gene Expression Profiling 4Methylprednisolone 3MLN 8237 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Immunoblastic Lymphadenopathy × visilizumab × Clear all
NCT00006009 2013-05-15

Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
DermatologicLymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡